干扰素治疗慢性丙型肝炎疗效分析  

Evaluation of treatment of chronic hepatitis C with interferon

作　　者：陈新月[1] 吴昊[1] 林秀玉[1] 汪俊韬[1] 

机构地区：[1]北京佑安医院,100054

出　　处：《中华肝脏病杂志》1999年第S1期11-13,共3页Chinese Journal of Hepatology

摘　　要：目的分析可能影响干扰素治疗慢性丙型肝炎疗效的因素。方法将慢性丙型肝炎62例，随机分成两组，治疗组42例应用干扰素治疗，对照组20例用一般保肝药物治疗，疗程6个月。分别于治疗前、疗程中及疗程后每隔3个月定期检测抗－HCVIgG和IgM，血清及本稍血单个核细胞（PBMC）中HCVRNA，ALT水平。疗程结束后致少随访1年．结果治疗结束及随访一年时治疗组和对照组的ALT的复常率为66．7％对300％和52．4％对15．0％，血清HCVRNAM转率分别为59．5％对15．0％和47．6％对10．0％。分析持久应答的影响因素，年轻、病程短，治疗前抗-HCVIgM抗体滴度高、PBMC中无HCV感染、病理诊断末合并肝硬化的患者对干扰素反应性较好。结论检测抗HCV-IgM及PBMC中HCVRNA可作为干扰素疗效的预测因素。Objective To evaluate the curative eftect of chronic hepatitis C (ch-c) with niterferon (IFN). Methods 62 proved cases of ch-c were graded, 42 cases were treated with IFN(α-2a), 20 cases were treated with general therapy. The course of treatment was. 6 months. The period of follow was 1year. The ALT, Anti-HCV-IgG IgM, HCV-RNA of serum and PBMC were tested regularly. Results In the treatment group and cotrast group, the ALT level returning to normal and serum HCV RNA transforming negative were 66.7%:30%, 52.4%:15% and 50.5%:15%, 47.6%:10% separately, in the end of treatment and follow. Conclusion The results suggested that the younger, shorter of disease course, the higher of Anti-HCV-IgM titre; PBMC with no infection of HCV and the biopsyproven with no cirrhosis could better fespond to IFN. For Patients with a sustained response, before treatment the higher Anti-HCV-IgM titre and PBMC HCV RNA negative may be predictive factors. [

关 键 词：丙型肝炎 慢性 干扰素 丙型肝炎病毒 外周血单个核细胞 

分 类 号：R512.63[医药卫生—内科学]